FDA decision: Saroglitazar by Zydus Therapeutics (this year)
As of Sat, 29 Aug 2026 22:02:04 UTC, Kalshi traders price Yes (73.0%). The market has $1K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 73.0% | 73.0¢ | 27.0¢ |
Market details
- Venue: Kalshi
- Volume: $1K
- Liquidity: $1K
- Closes:
Resolution rules
If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.
Sources
Related markets
- S&P close price end of 2026?
- Nasdaq-100 price on Sep 30, 2026 at 4pm EDT?
- Nasdaq-100 close price end of 2026?
- When will Anthropic officially announce an IPO?
- Who will successfully take over Warner Brothers?
- When will Apple release the iPhone 18?
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.